Viallat J R, Rey F, Astoul P, Boutin C
Paoli-Calmettes Institute, Marseilles, France.
Chest. 1996 Dec;110(6):1387-93. doi: 10.1378/chest.110.6.1387.
To assess the efficacy, permanence, and safety of thoracoscopic talc poudrage (TTP) for pleurodesis in malignant effusions.
Retrospective.
Patients with lifetime follow-up who received TTP in two related centers in Marseilles, France.
Three hundred sixty patients were included in this study: 88 had mesothelioma and 272 had pleural metastases. The mean follow-up time was 12 months (2 to 120). Of the 327 patients whose response could be evaluated, 90.2% had a successful pleurodesis at 1 month, and 82.1% had a life-long pleural symphysis. Adverse effects included 1 death 3 days after the procedure in a patient with end-stage disease, fever (9.8%), empyema (2.5%), pulmonary infection (0.8%), and malignant invasion of the scar (1 patient).
TTP is an effective and safe method of lifelong pleurodesis. It should be performed early on in the history of malignant effusions to avoid the risk of respiratory failure, this being directly linked to the general and respiratory status of the patients at the time of the procedure.
评估胸腔镜滑石粉喷洒术（TTP）用于恶性胸腔积液胸膜固定术的疗效、持久性及安全性。
回顾性研究。
在法国马赛两个相关中心接受TTP且有终生随访资料的患者。
本研究纳入360例患者：88例患有间皮瘤，272例有胸膜转移。平均随访时间为12个月（2至120个月）。在327例可评估反应的患者中，90.2%在1个月时胸膜固定术成功，82.1%有终生胸膜粘连。不良反应包括1例终末期疾病患者术后3天死亡、发热（9.8%）、脓胸（2.5%）、肺部感染（0.8%）以及瘢痕处恶性侵犯（1例患者）。
TTP是一种有效且安全的终生胸膜固定术方法。应在恶性胸腔积液病程早期进行，以避免呼吸衰竭风险，这与手术时患者的一般状况和呼吸状态直接相关。
